Through market attractiveness analysis, total addressable market evaluation, company benchmarking matrices, interactive Excel dashboards, expanded supply chain intelligence, emerging startup coverage, and detailed product insights, The Business Research Company’s 2026 market reports provide more actionable and strategically valuable research.
Sogroya Market Forecast Highlighting Growth From $ Billion To $ Billion
The historic period’s growth was driven by enhanced diagnostic methods for adult growth hormone deficiency, a broader reach of endocrinology specialty services, a wider supply of recombinant hormone treatments, rising recognition of adult GHD symptoms, and increased use of injectable hormone replacement approaches.
The expansion observed in the forecast period is driven by a growing need for less complicated hormone replacement schedules, a heightened emphasis on enhancing quality of life, the broadening scope of hormone therapy administered at home, increased funding for long-acting biologic treatments, and a growing trend among healthcare providers to favor weekly dosing schedules. Key developments shaping the forecast period consist of a rising uptake of sustained-release growth hormone therapies, an increasing demand for weekly treatments targeting adult growth hormone deficiency, a stronger push toward improving patient adherence to therapy, the advancement of pegylated hormone delivery systems, and a greater focus on ensuring patient convenience.
Download A Free Sample Report For Comprehensive Market Insights:
Sogroya Market Growth Factors Supporting Long-Term Expansion
The rising demand for hormone replacement therapy (HRT) is expected to drive the sogroya market forward in the coming years. HRT is a medical intervention aimed at replenishing hormones like estrogen and progesterone to alleviate symptoms related to menopause or hormonal imbalances. The growing use of hormone replacement therapy is fueled by a higher incidence of hormonal disruptions, enhanced public awareness of its advantages, and improvements in medical technologies that boost its accessibility and effectiveness for conditions such as menopause and growth hormone insufficiencies. Sogroya aids in hormone replacement therapy by offering a once-weekly treatment for individuals with growth hormone deficiency, aiding in the restoration of typical growth hormone levels, enhancing physical performance, and improving overall well-being through a convenient and effective dosing schedule. For example, according to the National Health Service (NHS), a UK government entity, in October 2025, approximately 14.7 million HRT items were prescribed during the most recent period, marking an 11% rise compared to 2023/24. Consequently, the escalating demand for hormone replacement therapy is fueling the sogroya market’s growth.
The expansion of the sogroya market is anticipated to be propelled by growing investments from the pharmaceutical industry. Pharmaceutical industry investment covers the financial resources that companies dedicate to endeavors such as research and development, clinical testing, production capabilities, and product launches to create, develop, manufacture, and market new drugs and therapies. These investments are on the rise due to a heightened demand for novel biologic therapies, prompting companies to allocate more funds toward sophisticated research and development to address unmet medical requirements. Sogroya contributes to pharmaceutical industry investment by providing a unique once-weekly growth hormone therapy that enhances company product portfolios, unlocks new market avenues, and supports sustained funding for advanced endocrine treatments. In December 2024, as reported by the Centers for Medicare & Medicaid Services, a US agency overseeing Medicare and Medicaid programs, U.S. healthcare spending surged by 7.5% in 2023, reaching $4.9 trillion, or roughly $14,570 per person. Thus, increased pharmaceutical industry investment is driving the sogroya market’s advancement.
Sogroya Market Segment Analysis: What Are The Major Market Categories?
The sogroya market covered in this report is segmented –
1) By Indication: Adult Growth Hormone Deficiency, Pediatric Growth Hormone Deficiency
2) By Formulation: Subcutaneous Injectable, Pre-Filled Syringes
3) By Distribution Channel: Retail Pharmacies, Online Pharmacies
4) By End User: Hospital, Clinicals, Ambulatory Care
Sogroya Market Industry Trends Shaping Future Revenue Growth
Leading players in the sogroya market are placing greater emphasis on securing regulatory approvals to broaden the drug’s approved uses and enhance patient access. Such approvals represent the official clearance provided by governmental bodies to confirm that a medication meets required standards for safety, effectiveness, and quality prior to its availability on the market or use in prescriptions. For example, in April 2023, Novo Nordisk A/S, a pharmaceutical firm based in Denmark, obtained approval from the U.S. Food and Drug Administration (FDA) for Sogroya to treat growth hormone deficiency in children aged 2.5 years and older. This decision made it the first once-weekly growth hormone therapy authorized for both pediatric and adult populations. The treatment is administered once a week via a subcutaneous injection, presenting a more convenient option compared to the daily injection regimen. The approval drew on findings from the phase 3 REAL4 study, which showed that height velocity outcomes with Sogroya were similar to those achieved with conventional daily somatropin. Among the commonly reported side effects are nasopharyngitis, headache, and reactions at the injection site.
Sogroya Market Leading Companies Driving Competitive Growth
Major companies operating in the sogroya market are Novo Nordisk A/S
Access The Complete Sogroya Market Report:
Sogroya Market Geographic Analysis: Where Is Demand Growing The Fastest?
North America was the largest region in the sogroya market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the sogroya market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/?utm_source=BlogsPR&utm_medium=Paid&utm_campaign=home_page_test
Americas: +1 310-496-7795
Asia: +44 7882 955267 & +91 8897263534
Europe: +44 7882 955267
Email us at: marketing@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model